Double Blind Placebo

DRUG3 trials

Sponsors

Janssen-Cilag International NV, AstraZeneca, Massachusetts General Hospital

Conditions

Attention Deficit Disorder With HyperactivityGastroesophageal Reflux Disease (GERD)Nicotine DependenceVaping

Phase 3

Open Label, Multicentre Extension Study of Protocol 42603ATT3002 to Evaluate Safety of Prolonged Release OROS Methlyphenidate in Adults With Attention Deficit Hyperactivity Disorder (ADHD)

CompletedNCT00307684

Janssen-Cilag International NVAttention Deficit Disorder With Hyperactivity

Start: 2006-01-31End: 2008-07-31Updated: 2014-04-21

Phase 3/Safety & Efficacy of Esomeprazole in Infants

CompletedNCT00468559

AstraZenecaGastroesophageal Reflux Disease (GERD)

Start: 2007-04-30End: 2008-06-30Updated: 2014-06-02

Phase 4

Varenicline for Nicotine Vaping Cessation in Adolescents

CompletedNCT05367492

Massachusetts General HospitalNicotine Dependence, Vaping

Start: 2022-06-22End: 2024-05-28Updated: 2025-04-27

Related Papers

Cannabis Use and Nicotine Vaping Cessation Outcomes: A Secondary Analysis of a Randomized Clinical Trial.

2025-12-01

Varenicline for Youth Nicotine Vaping Cessation

JAMA2025-04-2320 citations

A randomized controlled trial of varenicline and brief behavioral counseling delivered by lay counselors for adolescent vaping cessation: Study protocol

Frontiers in Psychiatry2023-03-154 citations